首页> 外国专利> Use of 17-(benzimidazol-1-yl)-androst-3-one and derivatives of 10ß-methyl-17-(benzimidazolyl)-cyclopent-16-eα hydro-phenanthrene in the manufacture of medicaments for treating androgen-dependent prostate diseases

Use of 17-(benzimidazol-1-yl)-androst-3-one and derivatives of 10ß-methyl-17-(benzimidazolyl)-cyclopent-16-eα hydro-phenanthrene in the manufacture of medicaments for treating androgen-dependent prostate diseases

机译:17-(苯并咪唑-1-基)-雄酮-3-酮和10ß-甲基-17-(苯并咪唑基)-环戊-16-e [α]氢菲的衍生物在制备用于治疗雄激素的药物中的用途前列腺依赖性疾病

摘要

Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic "addition-elimination" substitution reaction of 3²-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3²-ol or analogs thereof with tributylstannyl diazines. The compounds are potent inhibitors of human CYP 17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds are useful for the treatment of human prostate cancer.
机译:描述了类固醇C-17苯并唑,嘧啶并咪唑(氮杂苯并唑)和二嗪。还描述了它们的合成方法,包括具有步骤的3 2-乙酰氧基-17-氯-16-甲醛基-5,16-二烯或其类似物与苯并唑或嘧啶基吡咯亲核试剂的亲核乙烯基“加成-消除”取代反应的方法。以及具有钯催化的17-碘和十二烷基-5,16-dien-3 2 -ol或其类似物与三丁基锡烷基二嗪的交叉偶联反应的方法。这些化合物是人类CYP 17酶的有效抑制剂,也是野生型和突变雄激素受体(AR)的有效拮抗剂。该化合物可用于治疗人类前列腺癌。

著录项

  • 公开/公告号IL185608A

    专利类型

  • 公开/公告日2016-06-30

    原文格式PDF

  • 申请/专利权人 UNIVERSITY OF MARYLAND BALTIMORE;

    申请/专利号IL20070185608

  • 发明设计人

    申请日2007-08-30

  • 分类号A61K;A61P;C07J;

  • 国家 IL

  • 入库时间 2022-08-21 14:26:07

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号